Figure/The signing ceremony of technology transfer between NIH and Taiwei Biotechnology DBPR 1 15 was completed.
The first project DBPR 1 15 of "Asia-Pacific Biotechnology Pharmaceutical R&D Industry Center" is the research and development achievement produced by NIH Institute of Biotechnology and Drugs since 20 12, supported by the "Special Plan for Enterprise Science of the Ministry of Economic Affairs". Under the authorization of American Molecular Targeting Technology Company, the National Institutes of Health introduced a unique Zn-DPA drug delivery system that can identify tumors, and applied it to the development of new anticancer drugs. The team of the Institute of Biotechnology and Drugs has developed a connector technology that can effectively connect the drug delivery system and drugs, and has derived new patents. In order to promote the application and development of this technology by domestic manufacturers, in July 20 14, the National Institute of Health announced the biomedical innovation technology of Taiwan Province Biotechnology Month and solicited cooperation manufacturers. The following year1February, we entered into an industry-university cooperation with Taiwei Biotechnology to jointly carry out R&D work, and just won the 20 16 "Technical Achievement Award" from the Ministry of Economic Affairs. Today (818), the technology of DBPR 1 15 was officially transferred to Taiwei Biotechnology. Taiwei Biotechnology and the Institute of Biotechnology and Medicine of the National Institutes of Health jointly developed a new anticancer drug DBPR 1 15. Today (8/ 18), the project of "Asia-Pacific Biotechnology and Medicine R&D Industry Center" was promoted in Taiwan Province Province. This technical cooperation model is the first successful case of combining international and domestic industry-university cooperation in NIH.
Taiwei Biotechnology is a new drug development company jointly established by China Petrochemical (13 14) and Taivex (LLC) of the United States in February, 201year, and jointly developed with the consortium biotechnology center. Taiwei said that the company's operation mode is to continue "Industry-University-Research's cooperative development", help integrate and promote potential new drugs, and shorten the research and development time, so as to bring potential new drugs to the market as soon as possible and benefit more patients. Nowadays, the technology is transferred to this new anticancer drug with great market potential, and the subsequent preclinical trial development is taken over, which is expected to benefit cancer patients after the completion of human trials.
Only the dose of 1/5 has obvious response to colorectal cancer and pancreatic cancer. Compared with commercial targeted drugs using antibodies or nanoparticles as delivery systems, it has high stability and low production cost. At present, the experimental results show that DBPR 1 15 has a significant effect on colorectal cancer and pancreatic cancer, and its dosage is 1/5 of the original anticancer drugs on the market, which has several times the tumor growth inhibition effect. Because colorectal cancer ranks first in the number of common cancer patients in China in recent 8 years, the research and development of DBPR 1 15 will bring new hope for the treatment of colorectal cancer patients in China.
The three cores of "quality", "speed" and "value" strengthen international competitiveness. Focusing on quality, speed and value, the Institute of Biotechnology and Drug Research of the National Institutes of Health strengthens the international competitiveness of new drug research and development, with the vision of becoming an "Asia Center of Excellence for Innovative Drug Discovery (CEIDDA)", and * * * helps * * build an "Asia-Pacific biotechnology and drug research and development industry".
Subject: National Health Center